MaxCyte, Inc. announced a significant restructuring of its operations, which includes a reduction of approximately 34% of the company’s global workforce. This action is part of a broader strategic initiative to significantly reduce operating expenses, streamline the organizational structure, and accelerate MaxCyte's path toward profitability.
The company anticipates annualized savings of approximately $13.6 million as a direct result of this workforce reduction. This move is intended to yield meaningful cost savings while maintaining focus on MaxCyte's core mission of enabling the next generation of cell therapies.
MaxCyte reiterated its 2025 core revenue guidance to be flat to down approximately 10% compared to 2024, and its SPL program-related revenue guidance of approximately $5 million for the full year. The company expects to end 2025 with at least $155 million in cash, cash equivalents, and investments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.